According to research reviewed by Gram, a six-month pilot trial found that Hydroxiram D, a supplement combining amino acids, HMB, and vitamin D, produced a more favorable change in phase angle, a muscle health marker, in 32 people with early-stage liver scarring. Muscle mass and strength trends were positive but not statistically significant.
A small new clinical trial explored whether a supplement called Hydroxiram D could help people with early-stage liver scarring (cirrhosis) caused by fatty liver disease. Muscle loss is a common problem in people with liver disease, and it can affect health outcomes. Over six months, participants who took the supplement along with standard care showed a more favorable change in phase angle, a marker of muscle health, than those who received standard care alone. Differences in muscle mass, grip strength, and walking speed were not statistically significant, though they leaned in the supplement’s favor. No treatment-related side effects were reported. According to research reviewed by Gram, these are early findings that need larger, more rigorous studies before any firm conclusions can be drawn.
Key Statistics
A 2026 randomized pilot trial of 32 adults with early-stage fatty liver-related cirrhosis found that six months of Hydroxiram D led to a more favorable change in phase angle than standard care alone (+0.36 degrees versus -0.45 degrees, p = 0.046).
In the same 2026 pilot trial, no treatment-related adverse events were observed among participants taking Hydroxiram D for six months.
The 2026 study reported that differences in muscle mass, grip strength, and walking speed between groups were not statistically significant, although results leaned in the supplement group’s favor.
The Quick Take
- What they studied: Whether a supplement combining amino acids, a muscle-supporting compound called HMB, and vitamin D could improve muscle health in people with early liver scarring caused by fatty liver disease.
- Who participated: Thirty-two adults with early-stage liver scarring linked to fatty liver disease, which is often tied to metabolic conditions such as high blood sugar or obesity. All were treated at a single medical center.
- Key finding: After six months, the supplement group’s phase angle score improved by 0.36 degrees on average, while the standard care group’s score dropped by 0.45 degrees. This difference was statistically significant (p = 0.046), meaning it was unlikely to be due to chance alone, though the margin was narrow.
- What it means for you: This early result suggests the supplement may support muscle health in people with liver scarring, but it is not yet proven. Anyone with liver disease should talk with their doctor before starting any supplement.
The Research Details
This was a pilot study, which is a small first test designed to see whether a treatment is worth studying further. Researchers randomly assigned adults with early-stage liver scarring to one of two groups. One group received the supplement along with standard medical care, and the other received standard care alone. Random assignment helps make the groups similar at the start, so differences found later are more likely to come from the treatment itself.
The main measure was phase angle, a number that reflects how healthy cells are and how well the body holds muscle. Researchers also tracked muscle mass in the arms and legs, grip strength, and how fast participants could walk four meters. Each measure was checked at the start and after six months, and the analysis adjusted for starting values so that people with different baseline health were compared fairly.
The researchers also ran computer simulations after the trial. These were used only to help plan larger future studies, not to prove that the supplement works.
A randomized design is one of the strongest ways to test whether a treatment causes a change, because chance decides who gets the supplement. This makes the phase angle result more meaningful than it would be in a simple observational study. However, the small number of participants means the results could shift substantially in a larger trial.
Strengths include random assignment, a clear primary outcome chosen before the study, and statistical adjustment for starting differences. Readers should note that the sample was small, came from one center, and the study was described as a pilot, meaning it was designed to generate ideas rather than deliver definitive answers. The paper also notes that a double-blind design, where neither participants nor researchers know who receives the supplement, would strengthen future work. The journal is a peer-reviewed publication in physiology and biochemistry.
What the Results Show
The main result focused on phase angle, which is measured with a simple body scan that sends a tiny electrical current through the body. Higher phase angle numbers are generally associated with healthier cells and better muscle function. In this trial, the supplement group’s phase angle moved in a favorable direction, rising by 0.36 degrees, while the standard care group’s dropped by 0.45 degrees.
This difference reached statistical significance, meaning it met the study’s threshold for being unlikely to be random noise. The p-value of 0.046 sits just under the common cutoff of 0.05, so the result is considered borderline. A small shift in a single measure like this should be interpreted with caution, especially when the study is small.
Muscle mass, grip strength, and walking speed also trended in the supplement group’s favor. However, none of these differences were large enough to be considered statistically significant. Researchers described these as directional signals rather than proven benefits.
Importantly, no treatment-related side effects were observed during the six months, which is an encouraging safety signal, though a small trial may not detect rare problems.
The trend toward better muscle mass, grip strength, and walking speed matters because muscle loss in liver disease is linked to falls, hospital stays, and lower quality of life. Even though these changes were not statistically confirmed, they point in the same direction as the main finding. This consistency is one reason researchers believe the idea deserves a larger test. The lack of reported side effects also suggests the supplement was generally well tolerated over this period.
Muscle loss, called sarcopenia, is widely recognized as a common and serious complication in people with chronic liver disease. Previous research has suggested that amino acids, HMB, and vitamin D each play roles in maintaining muscle, which is why researchers combined them here. This trial adds early evidence that the combination may influence muscle health in this specific group, but it is among the first studies to test this exact formula in people with fatty liver-related cirrhosis. Larger studies would be needed to confirm how it compares with other nutritional approaches.
The most important limitation is the small sample of 32 people, which makes it harder to detect real differences and easier for chance to influence results. The study took place at a single center, so the findings may not apply to all patients or healthcare settings. The trial was also not double-blind as described in the abstract, which means expectations could have influenced how some measures were recorded or how participants felt. The main result was only borderline significant, and several secondary measures did not reach significance. The six-month timeframe is too short to tell whether the benefits last or whether they lead to fewer complications. Finally, the simulation analyses were exploratory and are not proof of effectiveness.
The Bottom Line
Based on this early trial, the evidence is preliminary, and confidence in the supplement’s benefit is low to moderate. Researchers recommend larger, prospectively registered, double-blind trials before any clinical recommendations are made. People with liver disease should continue their prescribed care and discuss any supplement with their medical team, since the trial found no reason for concern about safety in the short term but more evidence is needed.
People with early-stage liver scarring linked to fatty liver disease, along with their doctors and dietitians, may find this research of interest. Clinicians who manage muscle loss in liver patients may also want to watch for larger follow-up studies. People without liver disease, or those with more advanced liver problems, should not assume these results apply to them. Anyone who is pregnant, taking medications, or managing other health conditions should consult a healthcare provider first.
In this trial, changes were measured after six months, so that is the timeframe researchers used to observe any effects. Muscle changes typically develop gradually and require consistent nutrition and activity. Anyone considering a supplement should expect that any benefit, if it occurs, would take months rather than weeks, and they should not expect a quick fix. Long-term benefits and risks remain unknown.
Frequently Asked Questions
What is Hydroxiram D and what does it contain?
Hydroxiram D is a supplement combining branched-chain amino acids, HMB (a compound that supports muscle), and vitamin D. It was tested in a 2026 pilot trial of 32 adults with early-stage liver scarring caused by fatty liver disease, over six months.
Can supplements like Hydroxiram D help prevent muscle loss in liver disease?
Early research suggests they may help. A 2026 trial of 32 people found a more favorable phase angle, a muscle health marker, after six months. Researchers say larger, double-blind trials are needed before drawing firm conclusions about muscle protection.
Are there side effects from taking Hydroxiram D?
The 2026 pilot trial reported no treatment-related adverse events over six months in participants with early-stage liver scarring. Because the study was small and short, rare or long-term side effects could not be ruled out, so talk with your doctor first.
What is phase angle and why does it matter for muscle health?
Phase angle is a measurement taken with a simple body scan that sends a tiny electrical current through the body. Higher values are generally linked to healthier cells and better muscle function. It is one of several markers researchers use to track muscle health.
Want to Apply This Research?
- Track your daily protein intake in grams and your weekly walking time in minutes, and record your grip strength or a timed four-meter walk once a month if your care team approves. Share these numbers with your doctor during appointments.
- Use the app to set a daily reminder to take any supplement your doctor has approved, and log it each day. Pair this with a short daily walk, and record how many minutes you walk so you can see consistency over time.
- Review your logged protein intake, walking minutes, and supplement adherence weekly, and look for trends over several months rather than day-to-day changes. Bring the summary to clinic visits so your care team can compare it with lab and body composition results, and update your plan together.
This article summarizes an early, small pilot clinical trial and is for general information only. It is not medical advice. The findings are preliminary and have not been confirmed in larger studies. Anyone with liver disease or other health conditions should consult a qualified healthcare provider before starting, stopping, or changing any supplement or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.